Specialty Pharmacy

Marc O’Connor, chief operating officer at Curant Health, highlights upcoming trends to pay attention to within the specialty pharmacy landscape.

Top news of the day from across the healthcare landscape.

The lack of association of SVR with ribavirin dose reflects the wide variance in plasma levels between individuals with hepatitis C receiving the same weight-based dosage.

Top news of the week from Specialty Pharmacy Times.

Secretary of Labor to consider expanding access to Association Health Plans, which could allow employers to form groups across state lines.

Abemaciclib (Verzenio) may not improve overall survival in patients with non-small lung cancer.

Afatinib (Gilotrif) may treat patients with non-small cell lung cancer who have certain mutations.

Drinking coffee may have more profound survival benefits for patients with HIV and hepatitis C than for the general population.

Top news of the day from across the healthcare landscape.

DEA campaign called Operation Pilluted targets illegally diverted prescription medications.

Legislators are becoming more informed about DIR fees and their harms on Medicare beneficiaries and specialty pharmacies.

Many cancer drug approvals based on indirect measures, study finds.

An estimated 75% of patients with multiple sclerosis report fatigue among their most disabling disease symptoms.

Sheena Babin, PharmD, business development and clinical pharmacy manager at Ochsner Health System, discusses the importance of pharmacy residency programs.

A lack of biomarkers can result in a delay in multiple sclerosis diagnosis and treatment.

Top news of the day from across the healthcare landscape.

Current guidelines for treating children with HIV recommend regular medical visits for the first 2 years after care initiation.

Non-adherence to medication regimens is estimated to cost approximately $290 billion dollars in unnecessary medical expenses.

Cancer care at hospitals is significantly more expensive than at community oncology clinics.

Levels of certain bacteria and fungi appear to be higher among individuals with Crohn’s disease.

Two-drug combination of injectable, long-acting cabotegravir plus rilpivirine monthly or bi-monthly showed comparable efficacy to a daily 3-drug oral therapy at maintaining HIV-1 viral suppression.

Top news of the day from across the healthcare landscape.

Researchers continue to focus on developing an 8-week treatment regimen for hepatitis C virus.

Patients with ovarian cancer often face complex burdens that go beyond just medication.

A synthetic particle awakens dormant HIV cells then knocks them out.

The grant from the National Multiple Sclerosis Society aims to support the development of a potential oral treatment for progressive forms of MS.

An oncoprotein produced by the human papillomavirus results in cells that proliferate and do not die.

Moses Zoanna, CEO of Compliance Meds Technologies, discusses the impact of mobile health.